DK3356401T3 - Bindingsmolekyler med modificeret j-kæde - Google Patents

Bindingsmolekyler med modificeret j-kæde Download PDF

Info

Publication number
DK3356401T3
DK3356401T3 DK16784322.6T DK16784322T DK3356401T3 DK 3356401 T3 DK3356401 T3 DK 3356401T3 DK 16784322 T DK16784322 T DK 16784322T DK 3356401 T3 DK3356401 T3 DK 3356401T3
Authority
DK
Denmark
Prior art keywords
chain
modified
binding molecules
molecules
binding
Prior art date
Application number
DK16784322.6T
Other languages
Danish (da)
English (en)
Inventor
Bruce Keyt
Ramesh Baliga
Leonard George Presta
Original Assignee
Igm Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Igm Biosciences Inc filed Critical Igm Biosciences Inc
Application granted granted Critical
Publication of DK3356401T3 publication Critical patent/DK3356401T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK16784322.6T 2015-09-30 2016-09-30 Bindingsmolekyler med modificeret j-kæde DK3356401T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562235486P 2015-09-30 2015-09-30
PCT/US2016/055053 WO2017059387A1 (en) 2015-09-30 2016-09-30 Binding molecules with modified j-chain

Publications (1)

Publication Number Publication Date
DK3356401T3 true DK3356401T3 (da) 2020-09-07

Family

ID=57153544

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16784322.6T DK3356401T3 (da) 2015-09-30 2016-09-30 Bindingsmolekyler med modificeret j-kæde

Country Status (7)

Country Link
US (1) US11639389B2 (enExample)
EP (1) EP3356401B1 (enExample)
JP (1) JP7058213B2 (enExample)
CN (1) CN108463472A (enExample)
DK (1) DK3356401T3 (enExample)
ES (1) ES2819870T3 (enExample)
WO (1) WO2017059387A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014332458B2 (en) 2013-09-05 2020-03-12 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
EP3105250B1 (en) 2014-02-10 2020-08-05 IGM Biosciences, Inc. Iga multi-specific binding molecules
WO2015153912A1 (en) 2014-04-03 2015-10-08 Igm Biosciences, Inc. Modified j-chain
DK3247728T3 (da) 2015-01-20 2020-07-13 Igm Biosciences Inc Tumornekrosefaktor-(tnf)-superfamiliereceptorbindende molekyler og anvendelser deraf
KR20240135877A (ko) * 2015-03-04 2024-09-12 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
WO2016149201A2 (en) 2015-03-13 2016-09-22 Cytomx Therapeutics, Inc. Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
US10604559B2 (en) 2015-03-25 2020-03-31 Igm Biosciences, Inc. Multi-valent hepatitis B virus antigen binding molecules and uses thereof
CA2983034A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
BR112018000768A2 (pt) 2015-07-13 2018-09-25 Cytomx Therapeutics Inc anticorpos anti-pd-1, anticorpos anti-pd-1 ativáveis e métodos de uso dos mesmos
HK1252791A1 (zh) 2015-09-30 2019-06-06 Igm Biosciences, Inc. 具有经修饰的j链的结合分子
DK3356401T3 (da) 2015-09-30 2020-09-07 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
SG11201809336QA (en) * 2016-05-09 2018-11-29 Igm Biosciences Inc Anti-pd-l1 antibodies
WO2018017889A1 (en) * 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric gitr binding molecules and uses thereof
EP3607091A4 (en) 2017-04-07 2021-01-20 IGM Biosciences, Inc. MODIFIED HUMAN CONSTANT IGM REGIONS FOR THE MODULATION OF COMPLEMENT-DEPENDENT CYTOLYSIS EFFECTOR FUNCTION
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
US20200157224A1 (en) * 2017-06-25 2020-05-21 Systimmune, Inc. Multi-specific antibodies and methods of making and using thereof
CN110799546B (zh) * 2017-09-01 2023-01-24 四川科伦博泰生物医药股份有限公司 重组双特异性抗体
KR102839330B1 (ko) 2018-01-15 2025-07-30 난징 레전드 바이오테크 씨오., 엘티디. Pd-1에 대한 단일-도메인 항체 및 이의 변이체
AU2019224136A1 (en) * 2018-02-26 2020-09-10 Igm Biosciences, Inc. Use of a multimeric anti-DR5 binding molecule in combination with a chemotherapeutic agent for treating cancer
BR112020017296A2 (pt) 2018-03-01 2020-12-29 Igm Biosciences, Inc. Mutações de igm fc e de cadeia j que afetam a meia-vida sérica de igm
US11958903B2 (en) 2018-03-30 2024-04-16 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies against LAG-3 and uses thereof
US10654944B2 (en) * 2018-04-10 2020-05-19 Y-Biologics Inc. Cell engaging binding molecules
CN115991787A (zh) 2018-06-05 2023-04-21 江苏康宁杰瑞生物制药有限公司 二聚体及其用途
WO2019241721A2 (en) * 2018-06-14 2019-12-19 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Compositions and methods relative to igm memory b cells
CN113710706A (zh) * 2019-02-27 2021-11-26 豪夫迈·罗氏有限公司 用于抗tigit抗体和抗cd20抗体或抗cd38抗体治疗的给药
US20220220204A1 (en) * 2019-06-12 2022-07-14 Nanjing GenScript Biotech Co., Ltd. Anti-pd-l1/anti-lag-3 multiple antigen binding proteins and methods of use thereof
CN114450306B (zh) * 2019-07-26 2024-04-05 Abl生物公司 抗egfr/抗4-1bb双特异性抗体及其用途
WO2021022113A1 (en) * 2019-07-31 2021-02-04 The Wistar Institute Of Anatomy And Biology Multivalent dna antibody constructs and use thereof
JP2022544405A (ja) 2019-08-15 2022-10-18 アイジーエム バイオサイエンシズ インコーポレイテッド 免疫刺激性多量体型結合分子
MX2022002024A (es) * 2019-08-17 2022-03-11 Igm Biosciences Inc Moleculas de union anti-cd123 multimericas biespecificas y usos de estas.
WO2021055765A2 (en) * 2019-09-19 2021-03-25 Igm Biosciences, Inc. Multimeric antibodies with enhanced selectivity for cells with high target density
AU2021260928A1 (en) 2020-04-22 2022-10-27 Igm Biosciences, Inc. PD-1 agonist multimeric binding molecules
WO2022109023A1 (en) * 2020-11-17 2022-05-27 Igm Biosciences, Inc. Uses of effector cell engaging molecules with moieties of differing potencies
WO2022256740A1 (en) 2021-06-04 2022-12-08 Curia Ip Holdings, Llc Polymeric fusion proteins and compositions for inducing an immune response against infection
WO2023064766A1 (en) * 2021-10-11 2023-04-20 Igm Biosciences, Inc. Lateral flow device and uses thereof
CA3245061A1 (en) 2022-04-07 2023-10-12 Repertoire Immune Medicines, Inc. T-CELL RECEIVER MULTIMERS AND THEIR USES
WO2024148336A1 (en) * 2023-01-06 2024-07-11 Igm Biosciences, Inc. T cell costimulatory multimeric binding molecules and uses thereof

Family Cites Families (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8719963D0 (en) 1987-08-24 1987-09-30 Cattaneo A Recombinant dna products
US5831034A (en) 1987-11-13 1998-11-03 Hermann Katinger Human monoclonal anti-HIV-I-antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
DE69333950T2 (de) 1992-05-18 2006-08-17 Genentech, Inc., South San Francisco Aktivierung von Rezeptoren fähig zur Oligomerisierung durch Verwendung von fusionierten Rezeptor Liganden
US6476198B1 (en) 1993-07-13 2002-11-05 The Scripps Research Institute Multispecific and multivalent antigen-binding polypeptide molecules
UA40577C2 (uk) 1993-08-02 2001-08-15 Мерк Патент Гмбх Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин
AU697387C (en) 1994-09-16 2006-03-02 Austin Research Institute Cancer and Anti-inflammatory Syndicate No 1 Polypeptides with Fc binding ability
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
IL111196A0 (en) 1994-10-07 1994-12-29 Yeda Res & Dev Peptides and pharmaceutical compositions comprising them
US6808709B1 (en) * 1994-12-30 2004-10-26 The Regents Of The University Of California Immunoglobulins containing protection proteins and their use
US6165463A (en) * 1997-10-16 2000-12-26 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
CA2218515C (en) 1995-04-19 2008-10-07 Polymun Scientific Immunbiologische Forschung Gmbh Monoclonal antibodies against hiv-1 and vaccines made thereof
US20050003431A1 (en) 1996-08-16 2005-01-06 Wucherpfennig Kai W. Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses therefor
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
US6045774A (en) 1997-01-10 2000-04-04 Epicyte Pharmaceutical Inc. J chain polypeptide targeting molecule linked to an imaging agent
EP1015493A1 (en) * 1997-01-10 2000-07-05 EPIcyte Pharmaceutical, Inc. Novel epithelial tissue targeting agent
US20040009166A1 (en) 1997-04-30 2004-01-15 Filpula David R. Single chain antigen-binding polypeptides for polymer conjugation
US6284536B1 (en) 1998-04-20 2001-09-04 The Regents Of The University Of California Modified immunoglobin molecules and methods for use thereof
CN1342202A (zh) 1999-01-07 2002-03-27 津莫吉尼蒂克斯公司 可溶性受体br43×2和应用方法
WO2000061637A1 (en) 1999-04-14 2000-10-19 Smithkline Beecham Corporation Erythropoietin receptor antibodies
EP1194167B1 (en) 1999-06-09 2009-08-19 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
WO2001012820A1 (en) 1999-08-17 2001-02-22 Health Research Institute Genetic system and self-cleaving inteins derived therefrom, bioseparations and protein purification employing same, and methods for determining critical, generalizable amino acid residues for varying intein activity
CN1371416B (zh) 1999-08-24 2012-10-10 梅达里克斯公司 人ctla-4抗体及其应用
US20050287153A1 (en) 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
US20020168367A1 (en) 2000-04-28 2002-11-14 Planet Biotechnology Incorporated Novel immunoadhesins for treating and preventing viral and bacterial diseases
DE60139864D1 (de) 2000-04-28 2009-10-22 Planet Biotechnology Inc Immunoadhesin zur impfung gegen rhinovirus
MXPA02011092A (es) * 2000-05-10 2004-08-19 David A Sirbasku Composiciones y metodos para demostrar la regulacion del sistema inmune secretor del crecimiento de la celula de cancer que responde a la hormona esteroidea.
WO2002004522A2 (en) 2000-07-10 2002-01-17 Novartis Ag Bifunctional molecules and vectors complexed therewith for targeted gene delivery
US7972845B2 (en) 2000-09-07 2011-07-05 Case Western Reserve University Human antibodies against Pseudomonas aeruginosa LPS derived from transgenic xenomouse
US7138496B2 (en) 2002-02-08 2006-11-21 Genetastix Corporation Human monoclonal antibodies against human CXCR4
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
US7402312B2 (en) 2001-04-13 2008-07-22 Human Genome Sciences, Inc. Antibodies to vascular endothelial growth factor 2 (VEGF-2)
US20050129616A1 (en) * 2001-05-25 2005-06-16 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to TRAIL receptors
NZ513418A (en) 2001-08-07 2004-04-30 Univ Massey Vaccine comprising proteins from mycobacterium paratuberculosis
EP2360169B1 (en) 2001-10-23 2015-10-14 Psma Development Company, L.L.C. PSMA antibodies
EP2295468B1 (en) 2002-02-14 2015-07-08 Immunomedics, Inc. Anti-CD20 antibodies and fusion proteins thereof and methods of use
JP4472351B2 (ja) 2002-03-01 2010-06-02 イミューノメディクス、インコーポレイテッド インターナライジング抗ｃｄ７４抗体およびその使用方法
DE60325184D1 (de) 2002-03-01 2009-01-22 Immunomedics Inc Rs7 antikörper
BR0309254A (pt) * 2002-04-12 2005-03-01 Medarex Inc Uso de um anticorpo anti-ctla-4
MXPA04012656A (es) 2002-06-14 2005-08-15 Immunomedics Inc Anticuerpo hpam4 monoclonal humanizado.
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
AU2003250074B2 (en) 2002-07-18 2010-09-09 Merus N.V. Recombinant production of mixtures of antibodies
CA2494310A1 (en) 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
WO2004028339A2 (en) 2002-09-27 2004-04-08 Brigham And Women's Hospital, Inc. Treatment of patients with multiple sclerosis based on gene expression changes in central nervous system tissues
US7541440B2 (en) 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
EP1626992B1 (en) 2003-05-23 2010-06-02 Crucell Holland B.V. Production of recombinant igm in per.c6 cells
DE602004030451D1 (de) 2003-07-15 2011-01-20 Chugai Pharmaceutical Co Ltd Produktion von igm durch transformierte zellen und verfahren zur quantifizierung dieser igm-produktion
JP4733635B2 (ja) 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US7803914B2 (en) 2003-10-09 2010-09-28 Chugai Seiyaku Kabushiki Kaisha Methods for stabilizing protein solutions
KR20120125634A (ko) * 2003-10-16 2012-11-16 마이크로메트 에이지 다중특이적 탈면역화된 ｃｄ3-바인더
FR2861255B1 (fr) 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
EP1706425A2 (en) 2003-12-05 2006-10-04 John R. Schreiber Human anti-pseudomonas-aeruginosa antibodies derived from transgenic xenomouse®
WO2005077981A2 (en) 2003-12-22 2005-08-25 Xencor, Inc. Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
EP1814913B1 (en) 2004-11-05 2015-08-19 IGM Biosciences, Inc. Antibody induced cell membrane wounding
US7251164B2 (en) 2004-11-10 2007-07-31 Innovative Silicon S.A. Circuitry for and method of improving statistical distribution of integrated circuits
EP1833848A2 (en) 2004-12-09 2007-09-19 Lajolla Institute for Allergy and Immunology Novel tnf receptor regulatory domain
EP3332808B1 (en) 2005-03-03 2020-09-09 Immunomedics Inc. Humanized l243 antibodies
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
BRPI0611220A2 (pt) 2005-06-02 2010-08-24 Astrazeneca Ab anticorpos direcionados para cd20 e usos dos mesmos
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
JP2009521474A (ja) * 2005-12-21 2009-06-04 メディミューン，エルエルシー ＥｐｈＡ２ＢｉＴＥ分子およびその使用
CN101506358B (zh) 2006-05-15 2013-07-17 免疫医学股份有限公司 使用偶合的抗体或抗体片段治疗人免疫缺陷病毒感染的方法和组合物
EP2021500B1 (en) 2006-05-19 2014-12-31 Children, Youth and Women's Health Service Selective modulation of receptor signalling
EP2418223A3 (en) 2006-06-12 2013-01-16 Emergent Product Development Seattle, LLC Single-chain multivalent binding proteins with effector function
JP2010502224A (ja) 2006-09-08 2010-01-28 アボット・ラボラトリーズ インターロイキン１３結合タンパク質
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
US20080254512A1 (en) 2006-11-02 2008-10-16 Capon Daniel J Hybrid immunoglobulins with moving parts
US20080145420A1 (en) 2006-12-13 2008-06-19 Simon Michael R HUMAN SECRETORY IgA FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASES
WO2008114011A2 (en) 2007-03-19 2008-09-25 Medimmune Limited Fc polypeptide variants obtained by ribosome display methodology
US20100298223A1 (en) 2007-05-02 2010-11-25 Dietmar Rudolf Fries Fibrinogen for treatment of bleeding in trauma and platelet disorders
WO2009013620A2 (en) 2007-06-11 2009-01-29 Erasmus University Medical Center Rotterdam Homologous recombination
AU2007358569B2 (en) 2007-09-07 2014-09-04 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
CA2706700A1 (en) 2007-11-08 2009-05-14 Cytimmune Sciences, Inc. Compositions and methods for generating antibodies
EP2254592B1 (en) 2008-02-28 2019-06-05 Dako Denmark A/S Mhc multimers in borrelia diagnostics and disease
ITTO20080313A1 (it) 2008-04-22 2009-10-23 Marco Colombatti Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi
CN102149727A (zh) 2008-07-11 2011-08-10 航道生物技术有限责任公司 包含抗体替代卡帕轻链序列的构建体和文库
WO2010037402A1 (en) 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
CA2742968C (en) 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
US20120269830A1 (en) 2009-12-07 2012-10-25 Lawrence Horowitz Conjugates with improved pharmacokinetic properties
SI2519543T1 (sl) 2009-12-29 2016-08-31 Emergent Product Development Seattle, Llc Beljakovine, ki se vežejo s heterodimeri in njihova uporaba
WO2011100403A1 (en) 2010-02-10 2011-08-18 Immunogen, Inc Cd20 antibodies and uses thereof
RU2012138703A (ru) * 2010-02-11 2014-03-20 Алексион Фармасьютикалз, Инк. Терапевтические и диагностические способы с применением анти-cd200 антител
CA2815046C (en) 2010-10-19 2019-05-14 Mayo Foundation For Medical Education And Research Human antibodies and diagnostic and therapeutic uses thereof for the treatment of neurological disease
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
RU2014121043A (ru) 2011-10-24 2015-12-10 Эббви Инк. Биспецифические иммуносвязывающие средства, направленные против tnf и il-17
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
WO2013087912A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
JP6335796B2 (ja) 2012-02-08 2018-06-06 アイジーエム バイオサイエンシズ インク．Ｉｇｍ Ｂｉｏｓｃｉｅｎｃｅｓ Ｉｎｃ． Ｃｄｉｍ結合タンパク質及びその使用
CA2869023A1 (en) 2012-04-05 2013-10-10 Gottfried Himmler Secretory immunoglobulin complex
US20150175678A1 (en) 2012-06-15 2015-06-25 Beth Israel Deaconess Medical Center, Inc. IgA CD4i ANTIBODIES AND METHODS OF TREATMENT USING SAME
WO2014022592A1 (en) 2012-08-02 2014-02-06 Jn Biosciences Llc Antibodies or fusion proteins multimerized via cysteine mutation and a mu tailpiece
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
WO2014124457A1 (en) 2013-02-11 2014-08-14 University Of Louisville Research Foundation, Inc. Methods for producing antibodies
US9487773B2 (en) 2013-03-01 2016-11-08 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Cell-based methods for coupling protein interactions and binding molecule selection
EP2968587A2 (en) 2013-03-13 2016-01-20 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
GB201311487D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Bispecific molecules
US20150038682A1 (en) 2013-08-02 2015-02-05 Jn Biosciences Llc Antibodies or fusion proteins multimerized via homomultimerizing peptide
CA2917858A1 (en) 2013-08-02 2015-02-05 Aduro Biotech Holdings, Europe B.V. Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
AU2014332458B2 (en) 2013-09-05 2020-03-12 Igm Biosciences, Inc. Constant chain modified bispecific, penta- and hexavalent Ig-M antibodies
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
RU2016129959A (ru) 2013-12-30 2018-02-02 Эпимаб Биотерепьютикс Инк. Иммуноглобулин с тандемным расположением fab-фрагментов и его применение
WO2015107126A1 (en) 2014-01-16 2015-07-23 Mondelli Mario Umberto Francesco Neutralizing human monoclonal antibodies against hepatitis b virus surface antigen
EP3105250B1 (en) 2014-02-10 2020-08-05 IGM Biosciences, Inc. Iga multi-specific binding molecules
EP3660050A1 (en) * 2014-03-14 2020-06-03 Novartis AG Antibody molecules to lag-3 and uses thereof
WO2015153912A1 (en) 2014-04-03 2015-10-08 Igm Biosciences, Inc. Modified j-chain
DK3247728T3 (da) 2015-01-20 2020-07-13 Igm Biosciences Inc Tumornekrosefaktor-(tnf)-superfamiliereceptorbindende molekyler og anvendelser deraf
KR20240135877A (ko) 2015-03-04 2024-09-12 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
US10604559B2 (en) 2015-03-25 2020-03-31 Igm Biosciences, Inc. Multi-valent hepatitis B virus antigen binding molecules and uses thereof
CA2983034A1 (en) 2015-04-17 2016-10-20 Igm Biosciences, Inc. Multi-valent human immunodeficiency virus antigen binding molecules and uses thereof
CN108449940B (zh) 2015-07-12 2021-06-08 杭州多禧生物科技有限公司 与细胞结合分子的共轭偶联的桥连接体
HK1252791A1 (zh) 2015-09-30 2019-06-06 Igm Biosciences, Inc. 具有经修饰的j链的结合分子
DK3356401T3 (da) 2015-09-30 2020-09-07 Igm Biosciences Inc Bindingsmolekyler med modificeret j-kæde
SG11201809336QA (en) 2016-05-09 2018-11-29 Igm Biosciences Inc Anti-pd-l1 antibodies
WO2018017763A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric cd40 binding molecules and uses thereof
CA3030634A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric cd137/4-1bb binding molecules and uses thereof
AU2017298483A1 (en) 2016-07-20 2019-02-07 Igm Biosciences, Inc. Multimeric OX40 binding molecules and uses thereof
WO2018017889A1 (en) 2016-07-20 2018-01-25 Igm Biosciences, Inc. Multimeric gitr binding molecules and uses thereof
EP3607091A4 (en) 2017-04-07 2021-01-20 IGM Biosciences, Inc. MODIFIED HUMAN CONSTANT IGM REGIONS FOR THE MODULATION OF COMPLEMENT-DEPENDENT CYTOLYSIS EFFECTOR FUNCTION
AU2019224136A1 (en) 2018-02-26 2020-09-10 Igm Biosciences, Inc. Use of a multimeric anti-DR5 binding molecule in combination with a chemotherapeutic agent for treating cancer
BR112020017296A2 (pt) 2018-03-01 2020-12-29 Igm Biosciences, Inc. Mutações de igm fc e de cadeia j que afetam a meia-vida sérica de igm
SG11202103720XA (en) 2018-10-23 2021-05-28 Igm Biosciences Inc MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES
US20220106398A1 (en) 2019-02-08 2022-04-07 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof
JP2022544405A (ja) 2019-08-15 2022-10-18 アイジーエム バイオサイエンシズ インコーポレイテッド 免疫刺激性多量体型結合分子
MX2022002024A (es) 2019-08-17 2022-03-11 Igm Biosciences Inc Moleculas de union anti-cd123 multimericas biespecificas y usos de estas.
CA3149350A1 (en) 2019-08-23 2021-03-04 Igm Biosciences, Inc. Igm glycovariants
WO2021055765A2 (en) 2019-09-19 2021-03-25 Igm Biosciences, Inc. Multimeric antibodies with enhanced selectivity for cells with high target density
WO2021141902A1 (en) 2020-01-06 2021-07-15 Igm Biosciences, Inc. Highly sialylated multimeric binding molecules
AU2021260928A1 (en) 2020-04-22 2022-10-27 Igm Biosciences, Inc. PD-1 agonist multimeric binding molecules
KR20230010221A (ko) 2020-05-12 2023-01-18 아이쥐엠 바이오사이언스 인코포레이티드 암 치료를 위한 암 요법과 병용된 다량체 항-dr5 결합 분자의 용도
CA3187008A1 (en) 2020-07-27 2022-02-03 Paul R. Hinton Multimeric coronavirus binding molecules and uses thereof
WO2022109023A1 (en) 2020-11-17 2022-05-27 Igm Biosciences, Inc. Uses of effector cell engaging molecules with moieties of differing potencies
WO2022177870A1 (en) 2021-02-17 2022-08-25 The Board Of Regents Of The University Of Texas System Multimeric sars-cov-2 binding molecules and uses thereof
US20240076392A1 (en) 2021-02-17 2024-03-07 Igm Biosciences, Inc. Anti-cd123 binding molecules and uses thereof

Also Published As

Publication number Publication date
EP3356401A1 (en) 2018-08-08
JP7058213B2 (ja) 2022-04-21
US20190185570A1 (en) 2019-06-20
EP3356401B1 (en) 2020-06-24
CN108463472A (zh) 2018-08-28
WO2017059387A1 (en) 2017-04-06
ES2819870T3 (es) 2021-04-19
JP2018537410A (ja) 2018-12-20
US11639389B2 (en) 2023-05-02

Similar Documents

Publication Publication Date Title
DK3356401T3 (da) Bindingsmolekyler med modificeret j-kæde
IL287848A (en) Multispecific antigen binding molecules and their uses
DK3355913T3 (da) Bindingsmolekyler med modificeret j-kæde
IL259987A (en) Antibody molecules to pd-1 and uses thereof
IL257798A (en) Anti-lag-3 antibodies
DK3560954T3 (da) Modificeret j-kæde
EP3341477A4 (en) MANIPULATED CRISPR-CAS9 NUCLEASES
DK3177646T3 (da) Cd3-bindingsdomæne
GB201521858D0 (en) Small molecules
DK3248986T3 (da) Variable immunoglobulindomæner
DK3137843T3 (da) Projektil med forbedret ballistik
DK3242892T3 (da) Modificerede april-bindende antistoffer
IL253668A0 (en) Multivalent complexes containing dr5 binding regions
DK3105250T3 (da) Multispecifikke iga-bindingsmolekyler
DK3054976T3 (da) Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose
GB201601075D0 (en) Antibodies molecules
EP3506964A4 (en) BINDING SYRINGE
GB201522391D0 (en) Antibody molecules
DK3242685T3 (da) Cxcr4-bindende molekyler
EP3388693A4 (en) TERMINAL
DK3262182T3 (da) Modificeret creatinase
EP3960184C0 (en) PREECLAMPSIA
GB201503812D0 (en) Antibody molecules and uses thereof
EP3519034A4 (en) CHELATING MOLECULES
PL3122568T5 (pl) Książeczka zabezpieczona